LDS/Medical Tests/Immunohistochemistry for Burkitt lymphoma panel CD20, CD10, BCL-6, BCL-2, Ki-67

Immunohistochemistry for Burkitt lymphoma panel CD20, CD10, BCL-6, BCL-2, Ki-67

Burkitt lymphoma (BL) is a highly aggressive mature B-cell non-Hodgkin lymphoma characterized by rapid proliferation and a close association with MYC gene rearrangement. It most frequently affects children and young adults but can occur across all age groups. Histologically, BL exhibits a “starry-sky” pattern due to interspersed tangible-body macrophages within sheets of rapidly dividing neoplastic B cells. Immunohistochemistry (IHC) plays a crucial role in the diagnosis and differentiation of BL from other high-grade B-cell lymphomas. The Burkitt lymphoma panel includes CD20, CD10, BCL-6, BCL-2, and Ki-67, which collectively confirm B-cell lineage, germinal center origin, and proliferative activity:

  • CD20: A pan–B-cell marker confirming mature B-cell phenotype.
  • CD10 and BCL-6: Indicative of germinal center derivation, typical of BL.
  • BCL-2: Generally negative in classic BL, aiding distinction from other B-cell lymphomas (e.g., DLBCL, follicular lymphoma).
  • Ki-67: Proliferation index typically exceeds 95%, reflecting the tumor’s high mitotic rate.

This panel provides a comprehensive immunophenotypic profile essential for confirming the diagnosis of BL, differentiating it from morphologically similar entities such as DLBCL, and identifying cases of double-hit lymphoma when combined with molecular testing (e.g., MYC, BCL2, and BCL6 rearrangements).

  • As an aid in the diagnosis and management of Burkitt lymphoma
  • Differentiation diagnosis of Burkitt lymphoma from mantle cell lymphoma and other lymphomas
  • Provides prognostic information, as high Ki-67 correlates with aggressive clinical behavior
  • Assists in treatment planning, guiding the use of intensive, short-course chemotherapy regimens

Marker Expected Expression Interpretation: 

CD20 Positive Confirms mature B-cell lineage. 

CD10 Positive Indicates germinal center origin.

BCL-6 Positive Supports germinal center derivation.

BCL-2 Negative Absence supports BL; positivity may indicate alternative diagnosis (e.g., DLBCL).

Ki-67 >95% Extremely high proliferation index, characteristic of BL.

Negative for markers tested

Immunohistochemistry (IHC) using monoclonal antibodies specific for CD20, CD10, BCL-6, BCL-2, and Ki-67.

Formalin-fixed paraffin embedded (FFPE) tissue.

FFPE is stable at room temperature for longer.

MYC, BCL2, BCL6 FISH or by molecular method, Flow cytometry immunophenotyping, Complete blood count and metabolic panel.
4 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Blood Res. 2022 Apr 30;57(S1):55-61. [PMID: 35483927]
  • Ir Med J. 1975 May 24;68(10):247-54. [PMID: 1095525]
  • N Engl J Med. 2006 Jun 8;354(23):2431-42. [PMID: 16760443]
  • Hematol Oncol. 2010 Jun;28(2):53-6. [PMID: 19844983]
  • Burkitt Lymphoma. [Updated 2025 Feb 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538148/